Osteoporosis is the most common type of bone disease and induces serious consequences for public health. The main cause of osteoporosis is an imbalance between bone reabsorption and formation caused by osteoclasts and osteoblasts, respectively. Currently, beside nutrients, pharmacotherapy is the major therapeutic option for osteoporosis treatment. However, the fact that several commercialized drugs which are used to treat osteoporosis remaining side effects has raised a need for discovering new efficient and safer anti-osteoporosis compounds. In the traditional medicine, the medicinal plant Ban-chi-lien (Scutellaria barbata D.don) are widely applied to treat cancer patients. In a recent study, the authors had reported on the two novel compounds which were scutebata S and scutebata T isolated from S. Barbata. Those compounds had also ,exhibited some cytotoxic activity experimented on several cancer cell lines (Thao et al., 2014). In order to ekplore the more potential bioactivities of those novel compounds, the authors submitted them into anti-osteoporosis bioassay system. Therefore, in this study, an in vitro anti-osteoporosis activity of the scutebata S and scutebata T have been reported through their potential effects on MC3T3-E1 cell line. Namely, both scutebata S and scutebata T could stimulate the alkaline phosphatase activity, enhance extracellular matrix collagen synthesis and mineralization in MC3T3-E1 cells. Besides, the effect of scutebata T on formation of bone is higher than that of scutebata S and depends on its concentration. Especially, the middle concentration (e.g., 2 ug/ml) has showed the strongest impact of scutebata T compound on the proliferation of MC3T3-E1 cells (18.1 percent), enhanced ALP activity (25.03 percent), increased the secretion of collagen (18.02 percent), and induced the formation of calcium deposits (24.72 percent) compared with control. Whereas, scutebata S has stimulated differentiation of MC3T3-E1 cells strongest at 0.4 ug/ml.